Below is a list of studies we’ve done in the past.
- Meningitis for infants (Met41)
- Obesity Genetic Testing
- Pediatric Obesity
- Parainfluenza in toddlers using mRNA
- CMV using mRNA
- Pediculosis Capitis.
- Head Lice Infestation Treatment
- Type 2 Diabetes Mellitu Oral Semaglutide vs Sitagliptin
- Lira Prime Efficacy in controlling glycaemia with Victoza
- Lesinurad 200mg in Combinationwith a XanthineOxidase Inhibito
- Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control on Oral Therapy
- Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with or at High Risk for Cardiovascular Disease who are Statin Intolerant
- Efficacy and safety of two doses of favipiravir in older patients with uncomplicated influenza
- oseltamivir doses in influenza patients with pandemic (H1N1) 2009FLU
- A Dapagliflozin study in patients with type 2 diabetes and cardio vascular disease
- Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients with Type 2 Diabetes
- Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes with High BaselineHbA1c
- Evaluated Cardiovascular Outcomes with ITCA650 in Patients Treated with Standard of Care for Type 2 Diabetes
- Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) versusOseltamivir for the Treatment of Influenza in Adults at Risk for Complications
- CMV traditional vaccine
- HPV vaccine in males
- Type 2 Diabetes studies
- Testosterone in Men\
- FluMist Compared with (TIV) in Children
- (MMRV) versus ProQuad
- Respiratory Syncytial Virus in children
- Type 2 Diabetes Study to Assess Cardiovascular Outcomes with Ertugliflozin
- MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients
- Stain Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients with Hypertriglyceridemia
- Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza
- A “factorial” design, 12-month study to evaluate the efficacy and safety of AVE5530 25 mg/day and 50 mg/day co-administered with all registered atorvastatin
- A safety and tolerability of multiple oral doses of ASP1941in subjects with type 2 diabetes mellitus
- Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors
- Combination of Ertugliflozin with Sitagliptin in the Treatment of Subjects with T2DM with Inadequate Glycemic Control on Diet and Exercise
- Safety, and Tolerability of VK 2809 Administered for 12 Weeks Followed by a 6-Week Off-Drug Phase in Patients with Primary Hypercholesterolemia and a Non-Alcoholic Fatty Liver Disease
- Evaluate the Efficacy and Safety of Tenapanorfor Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
- Study of APT001Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers